Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 3
2009 1
2011 1
2013 3
2014 2
2016 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
Chevalier J, Giroud M, de Pouvourville G. Chevalier J, et al. Cerebrovasc Dis. 2013;35(4):320-6. doi: 10.1159/000347074. Epub 2013 Apr 23. Cerebrovasc Dis. 2013. PMID: 23615428
Prevention by anticoagulation or antithrombotic treatment is required, vitamin K antagonists (VKAs) and aspirin being the main agents. Dabigatran etexilate is a novel oral direct thrombin inhibitor. The RE-LY study demonstrated that in patients with AF, the rates of stroke …
Prevention by anticoagulation or antithrombotic treatment is required, vitamin K antagonists (VKAs) and aspirin being the main agents. Dabig …
Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J, Delaitre O, Hammès F, de Pouvourville G. Chevalier J, et al. Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):381-90. doi: 10.1016/j.acvd.2014.04.009. Epub 2014 Jun 24. Arch Cardiovasc Dis. 2014. PMID: 24973113 Free article.
The RE-LY atrial fibrillation study demonstrated that the rates of stroke and systemic embolism with dabigatran (an oral direct thrombin inhibitor) were similar to or lower than those with warfarin. AIMS: To estimate the cost-effectiveness, from a French payer perspective, …
The RE-LY atrial fibrillation study demonstrated that the rates of stroke and systemic embolism with dabigatran (an oral direct thrombin …
Valuing EQ-5D using time trade-off in France.
Chevalier J, de Pouvourville G. Chevalier J, et al. Eur J Health Econ. 2013 Feb;14(1):57-66. doi: 10.1007/s10198-011-0351-x. Epub 2011 Sep 21. Eur J Health Econ. 2013. PMID: 21935715
Implications of learning effects for hospital costs of new health technologies: the case of intensity modulated radiation therapy.
Bonastre J, Noël E, Chevalier J, Gerard JP, Lefkopoulos D, Bourhis J, Bensadoun RJ, de Pouvourville G; STIC IMRT 2002 Investigators. Bonastre J, et al. Among authors: chevalier j. Int J Technol Assess Health Care. 2007 Spring;23(2):248-54. doi: 10.1017/S026646230707033X. Int J Technol Assess Health Care. 2007. PMID: 17493311